Editor's Note: In the video, analyst Michael Douglass incorrectly states that Afrezza had a previous Advisory Committee positive recommendation. Afrezza has not been before an Advisory Committee before this round. The Motley Fool and the analyst regret the error.
MannKind (NASDAQ: MNKD ) has been on a tear since the beginning of the year, with the stock up over 50% year to date in large part due to a positive Advisory Committee recommendation for its inhaled insulin drug Afrezza. All eyes are now on the FDA, which has scheduled a Prescription Drug User Fee Action (PDUFA) date of July 15, 2014.
And if the FDA approves the drug, commercialization awaits. MannKind has not yet announced a marketing partner, and Pfizer's past difficulty marketing its own inhaled insulin, Exubera, is enough to give some investors pause.
In the video below, from Wednesday's edition of Where The Money Is, Motley Fool health care analyst Michael Douglass lays out why he is comfortable avoiding the stock for the time being.
Can even MannKind keep up with this top stock?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.